ClinicalTrials.gg
CompletedNCT03927157DIRECTIONUpdated Jul 1, 2025Results posted

Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

A Phase 3 interventional study of Experimental: Tezepelumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 72 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
405
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.

Enrollment
5th of 28
405 · median 121
Started
2019
with 4 others
Phase 3
16 of 28
4 open now
Registered
9th of 28
by date
Lead sponsor
16 of 28
AstraZeneca

Among the 28 studies testing tezepelumab in Asthma, this one is the 5th largest by enrollment, is one of 5 that started in 2019, is one of 16 in phase 3, and was the 9th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tezepelumab

tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tezepelumab in Asthma, or all of them as a file.
02

Study summary

A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma

Read the detailed description

This is a regional, multicentre, randomized, double-blind, placebo controlled, parallel group, phase 3 study designed to evaluate the efficacy and safety of 210 mg Q4W (SC) of tezepelumab in adults with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without OCS. Approximately 396 participants will be randomized regionally (China/non-China). Participants will receive tezepelumab, or placebo, administered via subcutaneous injection at the study site, over a 52-week treatment period. The study also includes a post-treatment follow-up period of 12 weeks

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Uncontrolled Asthma
  • Severe Uncontrolled Asthma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age. 18-80
  • Documented physician-diagnosed asthma for at least 12 months
  • Participants who have received a physician-prescribed asthma controller medication with medium or high dose ICS for at least 6 months.
  • Documented treatment with a total daily dose of either medium or high dose ICS (≥ 500 µg fluticasone propionate dry powder formulation equivalent total daily dose) for at least 3 months.
  • At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months.
  • Morning pre-BD \<80% predicted normal
  • Evidence of asthma as documented by either: Documented historical reversibility of FEV1 ≥12% and ≥200 mL in the previous 12 months OR Post-BD (albuterol/salbutamol) reversibility of FEV1 ≥12% and ≥200 mL during screening.
  • Documented history of at least 2 asthma exacerbation events within 12 months, and at least one of the exacerbations should occur during the treatment of medium-to-high dose ICS.
  • ACQ-6 score ≥1.5 at screening and on day of randomization

Exclusion criteria

Exclusion Criteria:

  • Pulmonary disease other than asthma.
  • History of cancer.
  • History of a infection.
  • Current smokers or participants with smoking history ≥10 pack-yrs.
  • History of chronic alcohol or drug abuse within 12 months.
  • , C or .
  • Pregnant or breastfeeding.
  • History of anaphylaxis following any biologic therapy.
  • participant randomized in the current study or previous tezepelumab studies.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
405 participants (actual)

Study arms

  • Experimental
    Tezepelumab

    Tezepelumab: Tezepelumab subcutaneous injection

    Biological: Experimental: Tezepelumab

  • Placebo comparator
    Placebo

    Placebo: Placebo subcutaneous injection

    Other: Placebo

Interventions

  • Tezepelumab subcutaneous injection

    Also known as: Tezepelumab

  • OtherPlacebo

    Placebo subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Annual Asthma Exacerbation Rate (AERR)

    The annual exacerbation rate is based on exacerbations reported by the investigator in the eCRF over 52 weeks

    Time frame: Randomization to Week 52

Secondary outcomes

  1. Mean Change From Baseline in Pre-dose/Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) at Week 52

    Mean change from baseline in FEV1 as compared to placebo at Week 52. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.

    Time frame: Randomization to Week 52

  2. Mean Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) Total Score at Week 52

    Mean change from baseline in AQLQ(S)+12 as compared to placebo at Week 52. The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma participants. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).

    Time frame: Randomization to Week 52

  3. Mean Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score at Week 52

    Mean change from baseline in ACQ-6 as compared to placebo at Week 52. The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.

    Time frame: Randomization to Week 52

  4. Mean Change From Baseline in Weekly Mean Daily Asthma Symptom Diary Score at Week 52

    Mean change from baseline in Asthma Symptom Diary score as compared to placebo at Week 52. The Asthma Symptom Diary comprises of 10 items (5 items in the morning; 5 items in the evening). Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the daily diary. A daily ASD score is the mean of the 10 items. A higher value indicates a worse outcome. Responses for all 10 items are required to calculate the daily ASD score; otherwise, it is treated as missing. For the 7-day average asthma symptom score, scoring is done with no imputation using the mean of at least 4 of the 7 daily ASD scores as a mean weekly item score. The 7-day average ASD score ranges from 0 to 4.

    Time frame: Randomization to Week 52

  5. Time to First Asthma Exacerbation

    Time to the first occurrence of asthma exacerbation post randomization, presented as number of participants with at least one asthma exacerbation reported in the eCRF

    Time frame: Randomization to Week 52

  6. Mean Change From Baseline in Fractional Exhaled Nitric Oxide at Week 52

    Mean change from baseline in FENO (ppb) at week 52 to assess the effect of 210 mg of tezepelumab SC Q4W on biomarkers

    Time frame: Randomization to Week 52

  7. Number of Participants With Asthma Specific Resource Utilization Over 52 Weeks

    Number of participants with asthma specific resource utilization (e.g. unscheduled physician visits, unscheduled phone calls to physicians, use of other asthma medications) over 52 weeks.

    Time frame: Randomization to Week 52

  8. Pharmacokinetics of Tezepelumab

    Mean serum trough PK concentrations taken pre-dose at each scheduled visit to evaluate the pharmacokinetics (PK) of tezepelumab

    Time frame: Baseline, Week 24, Week 52, Week 64

  9. Mean Change From Baseline in EQ-5D-5L VAS Score at Week 52

    Mean change from baseline in EQ-5D-5L VAS at week 52. EQ-5D-5L visual analogue scale (VAS) allows participants to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.

    Time frame: At Week 52

  10. Mean Change From Baseline in Blood Eosinophils (Cells/uL) at Week 52

    Mean change from baseline in blood eosinophil counts at week 52 to assess the effect of 210 mg of tezepelumab SC Q4W on biomarkers.

    Time frame: Randomization to Week 52

  11. Mean Change From Baseline in Total Serum IgE (IU/mL) at Week 52

    Mean change from baseline in IgE at week 52 to assess the effect of 210 mg of tezepelumab SC Q4W on biomarkers.

    Time frame: Randomization to Week 52

  12. Mean Change From Baseline in Night Time Awakenings (Percentage) at Week 52

    Mean change from baseline in night time awakenings due to asthma at Week 52. Night time awakenings percentage is defined as number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with available data and multiplied by 100%. At least 4 out of 7 days of data is required to calculate a weekly mean.

    Time frame: Randomization to Week 52

  13. Immunogenicity of Tezepelumab

    Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \>=2 post baseline assessments (with \>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment boosted ADA defined as baseline positive ADA that was boosted to a 4 fold or higher level following treatment. Treatment emergent ADA defined as sum of treatment induced ADA and treatment boosted ADA.

    Time frame: Baseline to Week 64

  14. Mean Change From Baseline in Daily Rescue Medication Use (Weekly Means) at Week 52

    Daily rescue medication use is defined as: Number of night inhaler puffs + 2 x \[number of night nebulizer times\] + number of daytime inhaler puffs + 2 x \[number of day nebulizer times\]. Weekly means are calculated using at least 4 of 7 days of daily rescue medication use.

    Time frame: Randomization to Week 52

  15. Mean Change From Baseline in Home Based Morning Peak Expiratory Flow (PEF) at Week 52

    Mean change from baseline in home based morning PEF (L/min) at Week 52. Home PEF testing was performed by participant in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.

    Time frame: Randomization to Week 52

  16. Mean Change From Baseline in Home Based Evening Peak Expiratory Flow (PEF) at Week 52

    Mean change from baseline in home based evening PEF (L/min) at Week 52. Home PEF testing was performed by participant in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.

    Time frame: Randomization to Week 52

  17. Annual Asthma Exacerbation Rate Resulting in Emergency Room Visit or Hospitalization

    The annual exacerbation rate is based on exacerbations reported by the investigator that are associated with an emergency room visit, urgent care visit, or a hospitalization (where urgent care visit was captured as an emergency room visit on the eCRF).

    Time frame: Randomization to Week 52

  18. Proportion of Participants Who Had no Asthma Exacerbations

    The proportion of participants who had no asthma exacerbations is presented as the percentage of participants with no exacerbations. This is defined as participants who meet both the following criteria: (1) completed the 52 week treatment period and (2) did not report an exacerbation during this period.

    Time frame: Randomization to Week 52

07

Results

Posted Jul 1, 2025

Participant flow

A total of 401 participants were randomized at 74 sites in 3 Asian countries to receive treatment with tezepelumab 210mg Q4W or placebo.

Participant flow — Overall Study
MilestoneTezepelumab 210mg Q4WPlacebo
Started201199
Completed186168
Not completed1531
Withdrew: Adverse event13
Withdrew: Protocol violation12
Withdrew: Withdrawal by subject821
Withdrew: Due to covid-19 pandemic52
Withdrew: Protocol-specified withdrawal criterion met02
Withdrew: Other than above01

Outcome measures

PrimaryAnnual Asthma Exacerbation Rate (AERR)

The annual exacerbation rate is based on exacerbations reported by the investigator in the eCRF over 52 weeks

Time frame:
Randomization to Week 52
Reported as:
Least squares mean · Events per year
Annual Asthma Exacerbation Rate (AERR)
Events per yearTezepelumab 210mg Q4WPlacebo
Annual Asthma Exacerbation Rate (AERR)0.42 (0.30 to 0.59)1.63 (1.22 to 2.19)
Statistical analysis
  • Tezepelumab 210mg Q4W vs Placebo · Negative Binomial Regression · p = <0.001 · Rate ratio: 0.26 · 95% CI 0.17 to 0.39
SecondaryMean Change From Baseline in Pre-dose/Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) at Week 52

Mean change from baseline in FEV1 as compared to placebo at Week 52. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.

Time frame:
Randomization to Week 52
Reported as:
Least squares mean · Litre
Mean Change From Baseline in Pre-dose/Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) at Week 52
LitreTezepelumab 210mg Q4WPlacebo
Mean Change From Baseline in Pre-dose/Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) at Week 520.35 ± 0.0290.11 ± 0.030
Statistical analysis
  • Tezepelumab 210mg Q4W vs Placebo · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.24 · 95% CI 0.16 to 0.32
SecondaryMean Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) Total Score at Week 52

Mean change from baseline in AQLQ(S)+12 as compared to placebo at Week 52. The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma participants. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).

Time frame:
Randomization to Week 52
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) Total Score at Week 52
Scores on a scaleTezepelumab 210mg Q4WPlacebo
Mean Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) Total Score at Week 521.29 ± 0.0740.94 ± 0.076
Statistical analysis
  • Tezepelumab 210mg Q4W vs Placebo · Mixed Models Analysis · p = 0.001 · Least squares means difference: 0.35 · 95% CI 0.14 to 0.55
SecondaryMean Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score at Week 52

Mean change from baseline in ACQ-6 as compared to placebo at Week 52. The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.

Time frame:
Randomization to Week 52
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score at Week 52
Scores on a scaleTezepelumab 210mg Q4WPlacebo
Mean Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score at Week 52-1.34 ± 0.058-1.03 ± 0.059
Statistical analysis
  • Tezepelumab 210mg Q4W vs Placebo · Mixed Models Analysis · p = <0.001 · Least squares means difference: -0.31 · 95% CI -0.47 to -0.15
SecondaryMean Change From Baseline in Weekly Mean Daily Asthma Symptom Diary Score at Week 52

Mean change from baseline in Asthma Symptom Diary score as compared to placebo at Week 52. The Asthma Symptom Diary comprises of 10 items (5 items in the morning; 5 items in the evening). Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the daily diary. A daily ASD score is the mean of the 10 items. A higher value indicates a worse outcome. Responses for all 10 items are required to calculate the daily ASD score; otherwise, it is treated as missing. For the 7-day average asthma symptom score, scoring is done with no imputation using the mean of at least 4 of the 7 daily ASD scores as a mean weekly item score. The 7-day average ASD score ranges from 0 to 4.

Time frame:
Randomization to Week 52
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in Weekly Mean Daily Asthma Symptom Diary Score at Week 52
Scores on a scaleTezepelumab 210mg Q4WPlacebo
Mean Change From Baseline in Weekly Mean Daily Asthma Symptom Diary Score at Week 52-0.61 ± 0.036-0.44 ± 0.037
Statistical analysis
  • Tezepelumab 210mg Q4W vs Placebo · Mixed Models Analysis · p = 0.001 · Least squares means difference: -0.16 · 95% CI -0.27 to -0.06
SecondaryTime to First Asthma Exacerbation

Time to the first occurrence of asthma exacerbation post randomization, presented as number of participants with at least one asthma exacerbation reported in the eCRF

Time frame:
Randomization to Week 52
Reported as:
Count of participants · Participants
Time to First Asthma Exacerbation
ParticipantsTezepelumab 210mg Q4WPlacebo
Time to First Asthma Exacerbation4589
SecondaryMean Change From Baseline in Fractional Exhaled Nitric Oxide at Week 52

Mean change from baseline in FENO (ppb) at week 52 to assess the effect of 210 mg of tezepelumab SC Q4W on biomarkers

Time frame:
Randomization to Week 52
Reported as:
Least squares mean · ppb
Mean Change From Baseline in Fractional Exhaled Nitric Oxide at Week 52
ppbTezepelumab 210mg Q4WPlacebo
Mean Change From Baseline in Fractional Exhaled Nitric Oxide at Week 52-15.88 ± 1.628-3.15 ± 1.658
SecondaryNumber of Participants With Asthma Specific Resource Utilization Over 52 Weeks

Number of participants with asthma specific resource utilization (e.g. unscheduled physician visits, unscheduled phone calls to physicians, use of other asthma medications) over 52 weeks.

Time frame:
Randomization to Week 52
Reported as:
Number · Participants
Number of Participants With Asthma Specific Resource Utilization Over 52 Weeks
ParticipantsTezepelumab 210mg Q4WPlacebo
Hospitalisation413
Emergency room visit511
Unscheduled visit to specialist3675
Home visit10
Telephone call2855
Ambulance transport02
SecondaryPharmacokinetics of Tezepelumab

Mean serum trough PK concentrations taken pre-dose at each scheduled visit to evaluate the pharmacokinetics (PK) of tezepelumab

Time frame:
Baseline, Week 24, Week 52, Week 64
Reported as:
Geometric mean · ug/mL
Pharmacokinetics of Tezepelumab
ug/mLTezepelumab 210mg Q4W
Baseline0 ± 0
Week 2421.3513 ± 43.96
Week 5221.2222 ± 41.51
Week 641.4450 ± 157.46
SecondaryMean Change From Baseline in EQ-5D-5L VAS Score at Week 52

Mean change from baseline in EQ-5D-5L VAS at week 52. EQ-5D-5L visual analogue scale (VAS) allows participants to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.

Time frame:
At Week 52
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in EQ-5D-5L VAS Score at Week 52
Scores on a scaleTezepelumab 210mg Q4WPlacebo
Mean Change From Baseline in EQ-5D-5L VAS Score at Week 5212.80 ± 1.0099.67 ± 1.028
SecondaryMean Change From Baseline in Blood Eosinophils (Cells/uL) at Week 52

Mean change from baseline in blood eosinophil counts at week 52 to assess the effect of 210 mg of tezepelumab SC Q4W on biomarkers.

Time frame:
Randomization to Week 52
Reported as:
Least squares mean · cells/uL
Mean Change From Baseline in Blood Eosinophils (Cells/uL) at Week 52
cells/uLTezepelumab 210mg Q4WPlacebo
Mean Change From Baseline in Blood Eosinophils (Cells/uL) at Week 52-193.44 ± 21.538-38.86 ± 21.984
SecondaryMean Change From Baseline in Total Serum IgE (IU/mL) at Week 52

Mean change from baseline in IgE at week 52 to assess the effect of 210 mg of tezepelumab SC Q4W on biomarkers.

Time frame:
Randomization to Week 52
Reported as:
Least squares mean · IU/mL
Mean Change From Baseline in Total Serum IgE (IU/mL) at Week 52
IU/mLTezepelumab 210mg Q4WPlacebo
Mean Change From Baseline in Total Serum IgE (IU/mL) at Week 52-92.77 ± 27.4600.30 ± 28.013
SecondaryMean Change From Baseline in Night Time Awakenings (Percentage) at Week 52

Mean change from baseline in night time awakenings due to asthma at Week 52. Night time awakenings percentage is defined as number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with available data and multiplied by 100%. At least 4 out of 7 days of data is required to calculate a weekly mean.

Time frame:
Randomization to Week 52
Reported as:
Least squares mean · Percentage of nights with awakenings
Mean Change From Baseline in Night Time Awakenings (Percentage) at Week 52
Percentage of nights with awakeningsTezepelumab 210mg Q4WPlacebo
Mean Change From Baseline in Night Time Awakenings (Percentage) at Week 52-18.74 ± 1.035-15.99 ± 1.093
SecondaryImmunogenicity of Tezepelumab

Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \>=2 post baseline assessments (with \>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment boosted ADA defined as baseline positive ADA that was boosted to a 4 fold or higher level following treatment. Treatment emergent ADA defined as sum of treatment induced ADA and treatment boosted ADA.

Time frame:
Baseline to Week 64
Reported as:
Number · Participants
Immunogenicity of Tezepelumab
ParticipantsTezepelumab 210mg Q4W (China Cohort)Placebo (China Cohort)Tezepelumab 210mg Q4W (Non-China Cohort)Placebo (Non-China Cohort)
ADA positive at baseline and/or post-baseline111837
Any baseline ADA positive101425
Only baseline ADA positive10725
Any post-baseline ADA positive11112
Both baseline and at least one post-baseline ADA positive0700
Treatment-induced ADA positive1412
Treatment-boosted ADA positive0110
TE-ADA positive1512
ADA persistently positive11011
ADA transiently positive0101
SecondaryMean Change From Baseline in Daily Rescue Medication Use (Weekly Means) at Week 52

Daily rescue medication use is defined as: Number of night inhaler puffs + 2 x \[number of night nebulizer times\] + number of daytime inhaler puffs + 2 x \[number of day nebulizer times\]. Weekly means are calculated using at least 4 of 7 days of daily rescue medication use.

Time frame:
Randomization to Week 52
Reported as:
Least squares mean · Inhalations and nebulizers per week
Mean Change From Baseline in Daily Rescue Medication Use (Weekly Means) at Week 52
Inhalations and nebulizers per weekTezepelumab 210mg Q4WPlacebo
Mean Change From Baseline in Daily Rescue Medication Use (Weekly Means) at Week 52-0.81 ± 0.064-0.70 ± 0.066
SecondaryMean Change From Baseline in Home Based Morning Peak Expiratory Flow (PEF) at Week 52

Mean change from baseline in home based morning PEF (L/min) at Week 52. Home PEF testing was performed by participant in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.

Time frame:
Randomization to Week 52
Reported as:
Least squares mean · L/min
Mean Change From Baseline in Home Based Morning Peak Expiratory Flow (PEF) at Week 52
L/minTezepelumab 210mg Q4WPlacebo
Mean Change From Baseline in Home Based Morning Peak Expiratory Flow (PEF) at Week 5246.70 ± 4.58618.96 ± 4.730
SecondaryMean Change From Baseline in Home Based Evening Peak Expiratory Flow (PEF) at Week 52

Mean change from baseline in home based evening PEF (L/min) at Week 52. Home PEF testing was performed by participant in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.

Time frame:
Randomization to Week 52
Reported as:
Least squares mean · L/min
Mean Change From Baseline in Home Based Evening Peak Expiratory Flow (PEF) at Week 52
L/minTezepelumab 210mg Q4WPlacebo
Mean Change From Baseline in Home Based Evening Peak Expiratory Flow (PEF) at Week 5242.14 ± 4.55816.81 ± 4.700
SecondaryAnnual Asthma Exacerbation Rate Resulting in Emergency Room Visit or Hospitalization

The annual exacerbation rate is based on exacerbations reported by the investigator that are associated with an emergency room visit, urgent care visit, or a hospitalization (where urgent care visit was captured as an emergency room visit on the eCRF).

Time frame:
Randomization to Week 52
Reported as:
Least squares mean · Events per year
Annual Asthma Exacerbation Rate Resulting in Emergency Room Visit or Hospitalization
Events per yearTezepelumab 210mg Q4WPlacebo
Annual Asthma Exacerbation Rate Resulting in Emergency Room Visit or Hospitalization0.07 (0.03 to 0.15)0.18 (0.09 to 0.34)
SecondaryProportion of Participants Who Had no Asthma Exacerbations

The proportion of participants who had no asthma exacerbations is presented as the percentage of participants with no exacerbations. This is defined as participants who meet both the following criteria: (1) completed the 52 week treatment period and (2) did not report an exacerbation during this period.

Time frame:
Randomization to Week 52
Reported as:
Number · Percentage
Proportion of Participants Who Had no Asthma Exacerbations
PercentageTezepelumab 210mg Q4WPlacebo
Proportion of Participants Who Had no Asthma Exacerbations74.650.3

Adverse events

Collected over Adverse events is collected from time of signature of the informed consent form until end of study at Week 64.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tezepelumab 210mg Q4W0/201 (0%)16/201 (8%)114/201 (56.7%)
Placebo2/199 (1%)36/199 (18.1%)125/199 (62.8%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventTezepelumab 210mg Q4WPlacebo
AsthmaRespiratory, thoracic and mediastinal disorders4/20117/199
PneumoniaInfections and infestations1/2014/199
Ovarian cyst rupturedReproductive system and breast disorders2/2010/199
Large intestine polypGastrointestinal disorders0/2011/199
Salivary gland massGastrointestinal disorders0/2011/199
DeathGeneral disorders0/2011/199
AppendicitisInfections and infestations0/2011/199
Covid-19Infections and infestations0/2011/199
Chronic sinusitisInfections and infestations0/2011/199
Coronavirus pneumoniaInfections and infestations0/2011/199
Most frequent other events
Showing 10 of 14
Most frequent other events
EventTezepelumab 210mg Q4WPlacebo
Upper respiratory tract infectionInfections and infestations71/20168/199
Covid-19Infections and infestations29/20125/199
Suspected covid-19Infections and infestations16/20125/199
NasopharyngitisInfections and infestations11/20116/199
PneumoniaInfections and infestations3/2019/199
Rhinitis allergicRespiratory, thoracic and mediastinal disorders3/2019/199
Respiratory tract infectionInfections and infestations1/2018/199
BronchitisInfections and infestations6/2017/199
PharyngitisInfections and infestations2/2017/199
Pneumonia bacterialInfections and infestations3/2017/199

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Tezepelumab 210mg Q4WPlaceboTotal
<=18 years000
Between 18 and 65 years166167333
>=65 years353267
Age, Continuous
Age, Continuous(Years)Tezepelumab 210mg Q4WPlaceboTotal
Mean52.3 ± 12.454.3 ± 10.353.3 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Tezepelumab 210mg Q4WPlaceboTotal
Female119112231
Male8287169
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tezepelumab 210mg Q4WPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino201199400
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tezepelumab 210mg Q4WPlaceboTotal
American Indian or Alaska Native000
Asian201199400
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

72 sites
  • Research Site
    Baotou, 14010, China
  • Research Site
    Beijing, 1000096, China
  • Research Site
    Beijing, 100020, China
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100070, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Beijing, 100853, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410011, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400000, China
  • Research Site
    Chongqing, 400016, China
  • Research Site
    Chongqing, 400038, China
  • Research Site
    Fuzhou, 350001, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Guangzhou, China
  • Research Site
    Guiyang, 550004, China
  • Research Site
    Haikou, 570311, China
  • Research Site
    Hangzhou, 310020, China
  • Research Site
    Hefei, 133500, China
  • Research Site
    Hengyang, 421001, China
  • Research Site
    Hohhot, 010017, China
  • Research Site
    Hohhot, 10050, China
  • Research Site
    Huzhou, 313003, China
  • Research Site
    Jinan, 250013, China
  • Research Site
    Jinhua, 321000, China
  • Research Site
    Kunming, 650032, China
  • Research Site
    Lanzhou, 730000, China
  • Research Site
    Linhai, 317000, China
  • Research Site
    Linyi, CN-276003, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 2100008, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Nanning, 530007, China
  • Research Site
    Quanzhou, 362000, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200050, China
  • Research Site
    Shengyang, 110004, China
  • Research Site
    Shenyang, 110015, China
  • Research Site
    Shenzhen, 518035, China
  • Research Site
    Shijiazhuang, 050000, China
  • Research Site
    Tianjin, 300192, China
  • Research Site
    Ürümqi, 830054, China
  • Research Site
    Weifang, 261041, China
  • Research Site
    Wenzhou, 325027, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Wuhan, 430033, China
  • Research Site
    Xi'an, 710004, China
  • Research Site
    Xining, 810007, China
  • Research Site
    Xuzhou, 221000, China
  • Research Site
    Xuzhou, 221009, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Zhengzhou, 450000, China
  • Research Site
    Zhuhai, 519099, China
  • Research Site
    Zibo, 255036, China
  • Research Site
    Zunyi, 563100, China
  • Research Site
    Iloilo City, 5000, Philippines
  • Research Site
    Quezon City, 1100, Philippines
  • Research Site
    Cheongju-si, 28644, South Korea
  • Research Site
    Daegu, 42415, South Korea
  • Research Site
    Jeonju, 54907, South Korea
  • Research Site
    Seoul, 03312, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 06591, South Korea
  • Research Site
    Suwon, 16499, South Korea
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in May 2024, 59 months.

Results were first posted in Jul 2025, 1 year 1 month after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 59 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2019
First posted
Apr 25, 2019
StartActual
Jun 14, 2019
Primary completionActual
May 24, 2024
CompletionActual
Aug 13, 2024
Results first posted
Jul 1, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03927157
Lead sponsor
AstraZeneca
Collaborators
Amgen
Responsible party
Sponsor
First posted
Apr 25, 2019
Start date
Jun 14, 2019
Primary completion
May 24, 2024
Completion
Aug 13, 2024
Results posted
Jul 1, 2025
Last update
Jul 1, 2025

Study contacts

Nanshan Zhong, Bachelor
principal investigator · Guangzhou institute of Respiratory Disease, China

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion